Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2025 14:06 ET | Source: BCC Research LLC

Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030

Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is...
September 08, 2025 08:30 ET | Source: Vivos Inc.

Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy

Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for...
March 19, 2025 06:00 ET | Source: Allogenica

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership

Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership Allogenica received a €2.5 million grant from the French government's France...
June 03, 2024 09:30 ET | Source: Ori Biotech Ltd

Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024

Ori Biotech and CTMC announce promising results for IRO, Ori’s newly launched next-generation CGT manufacturing enabling platform.
May 29, 2024 15:30 ET | Source: Ori Biotech Ltd

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference

Ori Biotech announces the commercial launch of IRO, a next-generation platform built to overcome the challenges of cell therapy manufacturing, at ISCT 2024
November 15, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players - Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec, DNAtrix, Treovir Istari

New York, USA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intratumoral Cancer Therapies Market to Observe Stupendous Growth During the Forecast Period (2023–2032), Assesses DelveInsight | Key Players -...
April 24, 2023 08:30 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers ...
April 12, 2022 13:53 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
January 27, 2021 20:30 ET | Source: DelveInsight Business Research LLP

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
October 27, 2020 08:30 ET | Source: Predictive Oncology

Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDAQ: POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an...